Target intelligence / Profile preview

Nuclear receptor subfamily 1 group D member 1 (NR1D1)

Target
NR1D1
Molecular classification
Nuclear receptor, Transcription factor, Ligand-dependent nuclear hormone receptor
01

Overview

Nuclear receptor subfamily 1 group D member 1 (NR1D1), also known as REV-ERBα, is a ligand-sensitive transcriptional repressor and a critical component of the circadian clock machinery. It regulates circadian rhythms, metabolic processes, and immune responses by binding to RORE sites on DNA and recruiting corepressor complexes. Heme is an endogenous ligand that stabilizes the interaction with corepressors. NR1D1 is a promising drug target for various diseases, including sleep disorders, metabolic syndrome, inflammatory diseases, cancer, and organ injury-related conditions, owing to its broad regulatory effects on autophagy, immunity, inflammation, metabolism, and aging.

Other names
REV-ERBαRev-ErbA alpha
02

Mechanism of action

Binds to RORE sites as a monomer or homodimer and recruits corepressor complexes such as NCOR and HDAC3, leading to histone deacetylation and transcriptional repression. Heme binding enhances corepressor interaction.

03

Biological functions

Circadian rhythm regulationMetabolic regulationImmune response regulationTranscriptional repression
04

Disease associations

Sleep disordersMetabolic syndromeInflammatory diseasesCancerOrgan injury-related diseases
05

Safety considerations

Potential for broad regulatory effects across multiple organsNeed for careful evaluation of long-term effects of pharmacological modulation
06

Interacting drugs

SR9009

Beyond the preview

Go deeper on Nuclear receptor subfamily 1 group D member 1 (NR1D1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuclear receptor subfamily 1 group D member 1 (NR1D1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call